Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.309 SNIP: 0.041 CiteScore™: 0.18

ISSN Print: 2151-8017
ISSN Online: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015014118
pages 195-214

Druggable Targets in Pancreatic Adenocarcinoma

Stefania Nobili
Department of Health Sciences, University of Florence, Firenze, Italy
Renato Tassi
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
Ida Landini
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
Gabriele Perrone
Department of Health Sciences, University of Florence, Firenze, Italy
Cristina Napoli
Department of Health Sciences, University of Florence, Firenze, Italy
Enrico Mini
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy

ABSTRACT

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death worldwide. It is often diagnosed at an advanced or metastatic stage and results of the approved systemic therapies are discouraging, making PDAC one of most lethal cancers in Western countries. In recent years, a better comprehension of PDAC unique biology has disclosed new potential targets for therapeutic interventions. Meanwhile, the development of conjugated agents, small molecules, antibodies, and immunoagents has opened therapeutic opportunities for drugs able to exert therapeutic effects on druggable targets of PDAC biology. Despite some failures, this approach is bringing meaningful results from bench to bedside, and more efficacious therapeutic opportunities may become available for PDAC treatment. In this review, we discuss the main hallmarks of PDAC biology as its microenvironment, cancer-driving proliferative pathways, growth suppression loops, and how PDAC evades immune system surveillance, as well as molecular aspects of each feature. The main preclinical and clinical results of each targeted intervention are also presented considering its biological rationale. Ongoing clinical trials provide evidence of the effectiveness of this approach and promising results in the treatment of PDAC.


Articles with similar content:

Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer
Critical Reviews™ in Eukaryotic Gene Expression, Vol.27, 2017, issue 2
Lian-wen Zheng, Dan-dan Li, Lu-lu Fu, Feng-ge Wang, Ying Xu, Xue-ying Zhang, Xu Zhou, Ling-yun Li, Shu-xiong Chen, Chun-jin Li
From Targets to Targeted Therapies in Hepatocellular Carcinoma
Forum on Immunopathological Diseases and Therapeutics, Vol.5, 2014, issue 3-4
Melchiorre Cervello, Antonella Cusimano, Maria Rita Emma, Antonina Azzolina, Giuseppa Augello, James A. McCubrey, Daniele Balasus
Therapeutic Intervention with Breast Cancer Metastasis
Critical Reviews™ in Eukaryotic Gene Expression, Vol.12, 2002, issue 2
Dina Chelouche Lev, Janet E. Price
Strategies to Strike Survival Networks in Cancer
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 3-4
Marzia Pennati, Giuliana Cassinelli, Graziella Cimino-Reale, Laura Gatti
Current Vaccination Strategies for the Treatment of B-Cell Lymphoma and Multiple Myeloma
Critical Reviews™ in Immunology, Vol.29, 2009, issue 5
Nurit Hollander